A veterinarian multinational company will test the Bionaturis vaccine against nematodes in livestock
Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has signed a contract with a multinational veterinarian company that will test the efficacy and safety of a vaccine to prevent livestock to be infected by intestinal nematodes -helminthes-. This agreement endorses Bionaturis strategic position as a supplier of vaccines for the veterinarian industry.
These gastrointestinal parasites cause annual losses of 3,000 million Euros in the livestock industry. To combat their effects, companies are using chemical endoparasticides that gradually lose efficacy due to growing phenomena of resistance. For this reason among others, governments and sectorial organizations are recommending a reduction of their use. In preliminary in-vivo tests, Bionaturis vaccine has shown superb protection against the types of helminthes that cause more problems and phenomena of resistance in the field. This product, encoded by the company as BNT004, is a first-in-class preventive treatment, and it could become a real and safe option against the most serious cases of resistance.
Efficacy higher than 65% in mice and lamb trials
BNT004 has already been tested in mice and lamb trials, showing protection values higher than 65%, in all cases, about the reduction of the number of parasites in vaccinated animals versus control. Besides, the vaccine is 100% safe and the treated animals did not show any symptomatology. As outstanding outcome for the livestock industry, challenged and vaccinated animals did not show a loss of weight versus control animals, whereas the challenged un-vaccinated animals did.
BNT004 is protected by a patent application of University of Granada (UGR), active in the main traditional veterinarian markets, out-licensed exclusively to Bionaturis back in 2012. Next trials will be made in the multinational company facilities and they will be finished in the first semester of 2014.
Javier Gallestegui, […]